



OPEN ACCESS

# Effects of plaque brachytherapy and proton beam radiotherapy on prognostic testing: a comparison of uveal melanoma genotyped by microsatellite analysis

Sophie Thornton ,<sup>1</sup> Sarah E Coupland,<sup>2</sup> Heinrich Heimann,<sup>3</sup> Rumana Hussain ,<sup>4</sup> Carl Groenewald,<sup>5</sup> Andrzej Kacperek,<sup>6</sup> Bertil Damato,<sup>7</sup> Azzam Taktak,<sup>8</sup> Antonio Eleuteri,<sup>8</sup> Helen Kalirai<sup>1</sup>

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/bjophthalmol-2019-315363>).

For numbered affiliations see end of article.

## Correspondence to

Dr Sophie Thornton, Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L7 8TX, UK; [sophie.thornton@liv.ac.uk](mailto:sophie.thornton@liv.ac.uk)

Received 8 October 2019

Revised 13 January 2020

Accepted 17 January 2020

## ABSTRACT

**Background/aims** Proton beam radiotherapy and plaque brachytherapy are commonly applied in primary uveal melanoma (UM); however, their effect on chromosome 3 classification of UM by microsatellite analysis (MSA) for prognostication purposes is unknown, where the tumour is sampled post-irradiation. This study examined the prognostic accuracy of genotyping UM biopsied before or after administration of radiotherapy, by MSA.

**Methods** 407 UM patients treated at the Liverpool Ocular Oncology Centre between January 2011 to December 2017, were genotyped for chromosome 3 by MSA; 172 and 176 primary UM were sampled prior to and post irradiation, respectively.

**Results** Genotyping by MSA was successful in 396/407 (97%) of UM samples (196 males, 211 females; median age of 61 years (range 12 to 93) at primary treatment). There was no demonstrable association between a failure of MSA to produce a chromosome 3 classification and whether radiation was performed pre-biopsy or post-biopsy with an OR of 0.96 (95% CI 0.30 to 3.00,  $p=0.94$ ). There was no evidence of association (measured as HRs) between risk of metastatic death and sampling of a primary UM before administration of radiotherapy (HR 1.1 (0.49 to 2.50),  $p=0.81$ ). Monosomy 3 (HR 12.0 (4.1 to 35.0),  $p<0.001$ ) was significantly associated with increased risk of metastatic death.

**Conclusions and relevance** This study revealed that successful genotyping of UM using MSA is possible, irrespective of irradiation status. Moreover, we found no evidence that biopsy prior to radiotherapy increases metastatic mortality.

## INTRODUCTION

In the management of primary uveal melanoma (UM), patients are increasingly being offered prognostic biopsy for genetic analysis of their UM to estimate metastatic risk. Because of the low DNA yield from some small tumour samples, microsatellite analysis (MSA) is often used to determine the copy number variation (CNV) of chromosome 3 (Chr3) for prognostic purposes. MSA was first successfully carried out in UM by Tschentscher *et al* in 2000,<sup>1</sup> and several studies have since confirmed its efficacy in accurately stratifying patients as having high or low metastatic risk.<sup>2–4</sup>

Most patients with uveal melanoma are treated with some form of radiotherapy.<sup>5–7</sup> The most common radiotherapy modalities employed in UM are plaque brachytherapy (PRXT) and proton beam radiotherapy (PBR).<sup>7–10</sup> Brachytherapy is most effective when used to treat small-to-medium sized UM where the thickness is  $\leq 7$  mm,<sup>11</sup> whereas PBR can be used to treat UM that are larger or closer to the optic disc and the fovea, taking advantage of the Bragg peak and utilising a modified beam structure.<sup>12</sup> Newer techniques, such as stereotactic radiosurgery with CyberKnife or Gamma Knife, achieve similar local control rates with eye retention to PBR but have a poorer visual prognosis post-treatment.<sup>13</sup>

The purpose of this study was to: (a) examine the mortality of patients with UM where Chr3 CNV was determined by MSA, (b) assess the effect, if any, of radiotherapy on successful Chr3 tumour classification and (c) establish whether sampling tumours before the administration of radiotherapy affects survival. Herein, we report MSA data from UM genotyped between 2011 and 2017 and including the largest cohort to date of UM samples obtained after PBR and PRXT, correlating these findings with genetic, histopathological and clinical data in addition to mortality.

## MATERIALS AND METHODS

### Tumour samples

A database query was carried out to identify all UM patients who were examined and treated at the Liverpool Ocular Oncology Centre (LOOC), Royal Liverpool and Broadgreen University Hospital Trust between January 2011 and December 2017, and who had genetic testing of their UM performed by MSA. All patients underwent a full systemic and ophthalmic examination at the LOOC and clinical, histopathological, genetic and follow-up data were collected. PBR was administered at the Clatterbridge Cancer Centre at a dose of 56 Gy over four consecutive days. Ruthenium PRXT delivered an apical tumour dose of a minimum of 80 to 90 Gy. Trans-retinal and trans-scleral tumour biopsy samples were obtained using methods described previously<sup>14</sup> either before or after radiotherapy. A single histology cytospin was produced for each biopsy and stained with May-Grünwald-Giemsa, as previously described.<sup>15</sup>



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.

**To cite:** Thornton S, Coupland SE, Heimann H, *et al*. *Br J Ophthalmol* 2020;**104**:1462–1466.

Confirmation of the presence of UM cells in the biopsy sample was undertaken by an experienced ophthalmic pathologist (SEC). All surgical resection samples (eg, enucleation, local resection, endoresection and iridocyclectomy) were processed using methods described previously.<sup>16–19</sup> Peripheral blood samples were collected at the time of surgical procedures to provide constitutional DNA used as a control in the MSA analysis.

This study was conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice Guidelines. All samples and data were provided by the Ocular Oncology Biobank (REC Ref 16/NW/0380). All patients had provided informed consent for the use of their samples and data in research.

### DNA extraction and genotyping by microsatellite analysis

DNA extraction was performed on UM tissue and blood samples as described by Lake *et al* (modified QIAamp and DNeasy Blood and Tissue kit; Qiagen, Crawley, UK).<sup>20</sup> DNA was resuspended in TE buffer (10 mM Tris-HCl pH 8.0, 0.1 mM EDTA) (Life Technologies Ltd, Carlsbad, California) and quantified using fluorometric methods (Invitrogen Qubit fluorometer and broad-range DNA quantification assay; Life Technologies, Carlsbad, California; Glasgow, UK). All samples tested by MSA had a DNA yield between 2 to 20 ng/ $\mu$ l. MSA was performed using a modified protocol from Thomas *et al*.<sup>4</sup> Briefly, genetic analysis was carried out using a polymerase chain reaction (PCR)-based technique assessing eight polymorphic microsatellite markers on Chr3; four microsatellite loci on 3p and four microsatellite loci on 3q (online supplementary table 2). All PCR steps were carried out on a G-Storm GS1 Thermal Cycler (Genetic Research Instrumentation Ltd, Essex) using the following conditions: initial activation step at 95°C for 15 min; and then 35 cycles of 94°C for 30 s, 56°C for 90 s and 72°C for 60 s with a final extension for 30 min at 60°C, cooling at 10°C. PCR products were loaded in 8.5  $\mu$ l Hi-Di Formamide containing 1  $\mu$ l LIZ500 size standard analysed using the ABI 3500 Genetic Analyzer. Fragment analysis was completed using GeneMapper V3.5 software (Applied Biosystems). An allelic ratio (AR) was calculated by normalising the allele peak area of the tumour against the corresponding blood sample (the control sample). The genotype of a locus was assigned based on the calculated AR: AR  $\geq$  2.5, loss of heterozygosity (LOH); AR 2.49 to 1.4, allelic imbalance (AI) or AR  $\leq$  1.39, no loss of heterozygosity (NLOH).

### Chr3 classification

A UM was classified as monosomy 3 (M3) when two or more microsatellites on chromosome arm 3p and two or more microsatellites on chromosome arm 3q showed LOH. UM were classified as disomy 3 (D3) when two or more microsatellites on chromosome arm 3p and two or more microsatellites on chromosome arm 3q showed NLOH. Partial loss (PL) of Chr3 was assigned if at least two markers were lost on one chromosome arm, when the other arm showed NLOH. UM, in which two or more microsatellites on chromosome arm 3p and two or more microsatellites on chromosome arm 3q showed AI, were classified as AI. When UM had two NLOH and two LOH on each arm, a tumour was classified as M3. UM were considered as ‘unclassifiable’, if none of the above conditions could be met<sup>15</sup> (online supplementary figure 1).

### Statistical analyses

Follow-up (years) was calculated from the date of the first diagnosis of the primary UM until death or study closure on 17<sup>th</sup> January 2019. Statistical analyses were carried out using IBM

SPSS Statistics V.24 (<https://www.ibm.com/products/spss-statistics>), Microsoft R 3.5.1, and the packages rms, cmprsk and mstate (<https://mran.microsoft.com/>). Because of the small sample size, to control the false discovery rate, the statistical significance was defined as  $p < 0.001$  (two-sided).

## RESULTS

### Patient demographics

From January 2011 to December 2017, 407 UM patients receiving treatment at the LOOC underwent genotyping for Chr3 using MSA (online supplementary table 1). The study cohort comprised 196 males and 211 females with a median age of 61 years at primary management (range 12 to 93 years). The median follow-up was 54 months (range 5 to 368 months). The UM had a median largest basal diameter of 11.2 mm (range 1.8 to 20.8 mm) and a median ultrasound height of 3.1 mm (range 0.9 to 18.5 mm). UM involving the ciliary body was 53/407 (13%) and 5/407 (1%) had extraocular extension. The tumour size category according to the eighth AJCC (American Joint Committee on Cancer) TNM classification system was: T1 in 186 cases (46%), T2 in 146 cases (36%), T3 in 59 cases (14%) and T4 in 16 cases (4%). On histological examination, 116/407 (29%) UM samples contained epithelioid cells.

At the time of study closure on 17<sup>th</sup> January 2019, 347/407 (85%) patients were alive, 35/407 (9%) patients had developed or died from metastatic disease, 20/407 (5%) patients died from other or unknown causes and 5/407 (1%) patients were lost to follow-up.


Nine of the 407 UM samples (2%) analysed were diagnostic biopsies: 6/9 went on to have secondary enucleations; 1/9 had a subsequent endoresection with 2/9 receiving no further treatment.

The 407 examined UM samples consisted of: 359 intraocular biopsies, 31 enucleations, 4 local resections, 10 endoresections and 3 iridocyclectomies (figure 1). Seven cases analysed were excluded from the time to biopsy analysis following radiotherapy due to sampling more than 2 years after radiotherapy treatment ( $n=4$ ) and overseas patients who were lost to follow-up ( $n=3$ ), leaving 345 cases that had received radiotherapy.

Of the 345 UM patients that received radiotherapy, 169 (49%) and 176 (51%) were sampled pre-radiotherapy and post-radiotherapy, respectively. The median time interval between biopsy and PBR was 32 days with the range spanning from 66 days preoperatively (including some diagnostic biopsies) to 284 days postoperatively. Similarly, the median time interval between biopsy and PRXT was 0 days with the range spanning from 49 days preoperatively to 129 days postoperatively. Of the 176 samples analysed post-radiotherapy only six (3%) failed to provide a Chr3 classification. The median time to biopsy of these six cases was 36.5 days (range 24 to 52).

### Microsatellite analysis

UM samples successfully genotyped were 395/407 (97%) according to the MSA classifications described in Materials and Methods: 97 (24%) UM were M3 (20% of AJCC 1, 48% AJCC 2, 20% AJCC 3 and 9% AJCC 4), 256 (63%) UM were D3 (53% AJCC 1, 32% AJCC 2, 13% AJCC 3 and 2% AJCC 4), 16 (4%) UM were PL, all loss of 3q, (50% AJCC 1, 31% AJCC 2 and 19% AJCC 3) and 26 (6%) UM were AI (54% AJCC 1, 35% AJCC 2, 8% AJCC 3 and 3% AJCC 4). Further, 12 (3%) UM were considered ‘unclassifiable’ (67% AJCC 1, 25% AJCC 2 and 8% AJCC 3). Of these, 6/12 (50%) were sampled pre-radiotherapy and 6/12 (50%) post-radiotherapy. Of the 35 UM patients who



**Figure 1** Flowchart of specimens examined in the present study; n=407 samples examined, n=353 received radiotherapy either n=136 proton beam radiotherapy or n=217 ruthenium plaque radiotherapy; n=174 samples were taken before administration of either proton beam or plaque radiotherapy of which n=6 failed genotyping; n=179 samples were taken after administration of either proton beam or plaque radiotherapy of which n=6 failed genotyping. MSA, microsatellite analysis; RT, radiotherapy; UM, uveal melanoma.

died of metastatic UM, 27 (77%) had M3 UM, 2 (6%) had loss of 3q, 5 (14%) were D3 and 1 (3%) was ‘unclassifiable’.

For samples taken pre-radiotherapy and post-radiotherapy, the genetic results were comparable and there was no significant difference in the number of UM cases for which Chr3 data (either M3, D3, PL or AI) was obtained ( $X^2 p=0.099$ ).

**Cox analysis**

The data set comprised of 345 complete observations. The variables used in the analysis are shown in table 1.

Table 1 Characteristics of 345 UM cases genotyped either before or after RXT	
Variable	n=345
Chromosome 3 classification	D3: 216 (63%) AI: 23 (7%) Loss 3q: 14 (4%) M3: 80 (23%) Unclassifiable: 12 (3%)
Genotyping	Successes: 333 (97%) Failures: 12 (3%)
Biopsy before/after RXT	Before: 169 (48%) After: 176 (52%)
Survival status	Censored: 305 (88%) Metastasis death: 24 (7%) Other causes death: 16 (5%)
Follow-up (years)	Min: 0.41 Max: 8

AI, allelic imbalance; D3, disomy 3; M3, monosomy 3; RXT, radiotherapy; UM, uveal melanoma.

Table 2 Cox model statistics			
Factor	HR (95% CI)	Z test P value	PH $\chi^2$ test P value
Biopsy before RXT	1.1 (0.49 to 2.5)	0.81	0.56
Chr3 – unclassifiable	5.5 (0.61 to 49)	0.13	0.65
Chr3 – monosomy	12 (4.1 to 35)	<b>0.0000073</b>	0.39
Chr3 – loss 3q	7.4 (0.82 to 66)	0.075	0.65
Chr3 – allelic imbalance	–	–	–

Chr3, chromosome 3; RXT, radiotherapy.

A Cox proportional hazards model<sup>21</sup> was fitted to assess the impact on metastatic death hazard rate of biopsy sampling before or after radiotherapy and Chr3 classification. Contrasts were specified so D3 was the baseline level, and the hazard rate for the other four Chr3 classes are specified in relation to D3.

The hypothesis of the proportionality of hazards was assessed.<sup>21</sup> Table 2 shows the HRs, p values of the z statistics and proportionality of hazards test for each factor. There is evidence only of a difference between hazard rates associated to M3 and D3.

Because of the small number of metastatic deaths, the 95% CIs on the HRs of Chr3 classes were wide; in the case of AI, no metastatic events occurred, so the model parameters could not be identified.


The C-index<sup>21</sup> with 95% CI was 0.78 (0.69 to 0.87), denoting good discrimination performance.

**Logistic regression**

A logistic regression model<sup>21</sup> was fitted to assess the impact of biopsy sampling before or after radiotherapy on the success of genotyping. There was no evidence of this factor affecting the success of genotyping by MSA, with OR of 0.96 (95% CI 0.30 to 3.0, p=0.94)

**Cumulative incidence analysis**

Figure 2 shows the cumulative incidence (c.i.) of metastatic death by Chr3 levels. No metastatic death events were observed in the AI group, so the cumulative incidence was zero. It should be noted that the Loss 3q c.i. and Unclassifiable c.i. were essentially the same, overlapping with M3 c.i. up to about 3 years.



No. at risk	D3	216	215	187	149	124	100	62	23	1
M3	80	79	68	56	47	37	24	11		
AI	23	22	16	15	10	9	6	2		
PL	14	14	6	5	2	1	1			
U	12	12	11	7	7	3	2			

**Figure 2** Cumulative incidence functions and number at risk for each time interval, by Chr3 level. AI, allelic imbalance; Chr3, chromosome 3; D3, disomy; M3, monosomy; PL, partial loss3q; U, unclassifiable.

Furthermore, the estimated 95% confidence limits on Loss 3q c.i. and Unclassifiable c.i. (not shown to avoid clutter) were so large that they enclosed both the M3 and D3 c.i.

Gray's K-sample test statistic<sup>22</sup> for comparing the c.i. across the Chr3 levels is  $G=34$  ( $p<0.001$ ). This result qualitatively agreed with the Cox analysis, and the difference could be attributed mostly to M3 and D3.

## DISCUSSION

To our knowledge, this is the largest series of post-radiotherapy UM samples genotyped for Chr3 status to date. We have shown that MSA can be used to establish Chr3 status in 97% of cases. Taking a biopsy before administration of radiotherapy did not increase the risk of metastatic death. Furthermore, neither PBR nor PRXT affected genotyping classification.

MSA is a molecular technique that can accurately determine Chr3 status in small UM biopsy samples with low DNA concentrations.<sup>23</sup> In our study, genotyping was successful in 97% of all cases examined resulting in classification into two main groups, M3 and D3. The Chr3 classifications show evidence of an increased (with respect to D3) hazard of metastatic death in the case of M3, but no evidence for the other classes. Effects could not be reliably estimated in the case of AI because of a lack of associated metastatic death events. In all cases, the small number of events translates into large uncertainties in the estimation of HRs. Analysis of cumulative incidences provides qualitatively similar results. Of interest, a large proportion of M3 classifications by MSA were observed in AJCC stages 1 and 2 highlighting that smaller tumours are not immune from being at high risk of developing metastases. This is consistent with the findings of Damato *et al* who demonstrated many small tumours showed risk factors for metastasis, such as M3.<sup>24</sup> Cases with PL of Chr3 and AI were also observed. PL of Chr3 in this study occurred exclusively as loss of 3q in 4% of the UM genotyped. Thomas *et al* also reported PL of Chr3 in 4% of UM cases analysed by MSA, while in the study by Shields *et al* PL of Chr3 was detected in 27% of UM cases.<sup>4,23</sup> The incidence of PL of Chr3 varies greatly in the literature, with some studies reporting it to be between 0% and 48% by MSA and other techniques.<sup>3</sup> It is suggested that PL of Chr3 is caused by tumour heterogeneity. Cytomorphological heterogeneity is well documented in posterior UM and has led to concerns that extracting a biopsy from a single site may not be representative of the whole tumour.<sup>25,25</sup> Heterogeneity of gene loci dosage quotients was reported in a study utilising multiplex ligation-dependent probe amplification (MLPA) to examine CNV in UM; however, this did not affect the overall CNV classification.<sup>26</sup> In the present study, eight UM patients underwent a subsequent enucleation following biopsy, and the prognostic results were concordant for each of these. Similarly, Coupland *et al* reported concordant Chr3 data for patient-matched samples in 28 UM cases that were initially biopsied and subsequently resected.<sup>27</sup>

In this study, no patients with AI developed metastatic disease; however, because of the small number of cases with this classification, no conclusive association of AI with mortality could be made. AI was first reported by Tschentscher *et al* who consistently observed allele ratios that fell just below the cut-off thresholds for gain or loss.<sup>1</sup> They reasoned that this may be the result of clonal heterogeneity or more focal dosage changes. Thomas *et al* demonstrated that UMs with AI showed survival similar to those with M3 UM, and thus were associated with a poor prognosis.<sup>4</sup> In their study, UM were defined as 'AI' if at least two markers showed AI even if the remaining markers were LOH, which in the current study would have been classified as M3.

The impact of taking a biopsy before or after radiotherapy on the success of genotyping was also assessed, using a logistic regression model. The OR shows no evidence of an effect, but it should be considered the small number of failed genotyping entries, which tends to bias the classification towards the class with the largest number of entries (in this case, successful genotyping). These data are, however, consistent with the results of Hussain *et al* who demonstrated that genetic analysis of UM by MLPA and MSA after treatment with PBR provided Chr3 classifications predictive of metastasis free survival.<sup>14</sup> Similarly, in a study by Coupland *et al* four UM samples obtained both pre-radiotherapy and post-radiotherapy showed concordant genetic results, demonstrating successful genotyping of irradiated specimens.<sup>27</sup> Another analysis by Wackernagel *et al* utilised array comparative genomic hybridisation to test samples pre-radiotherapy and post-radiotherapy; five patients had genetic analysis done before and after radiotherapy, and their results were also completely concordant, thus confirming the suitability of these samples for genotype analysis.<sup>28</sup> This was not the case in the study by Dogrusöz *et al* who used karyotyping and fluorescence in situ hybridisation to genotype irradiated tumours.<sup>29</sup> Analysis of these samples was largely unsuccessful mainly due to tumour shrinkage and necrosis associated with irradiation, and in comparison to other studies, there was a significantly longer time from irradiation until enucleation (5 to 146 months). Most recently, Matet *et al* demonstrated genetic concordance of clinically relevant chromosomes in 94% of matched biopsies taken before PBR and a subsequent endoresection taken less than 3 months following radiotherapy.<sup>30</sup>

To our knowledge, this is the first study of its kind to examine whether taking a biopsy before treatment by radiotherapy is associated with death from metastatic UM. An *ex vivo* study performed by Glasgow *et al* demonstrated iatrogenic dissemination of tumour cells following transvitreal biopsy.<sup>31</sup> There have also been other case reports and series of suspected dissemination, which has contributed to the reluctance of some ophthalmologists to take diagnostic and prognostic biopsies.<sup>32–35</sup> In this study, Cox analysis shows no evidence that a biopsy taken before or after radiotherapy affects the metastatic event hazard rate. This is consistent with the findings of a recent study by Bagger *et al* where a retrospective nationwide audit of 1637 UM patients demonstrated that melanoma-specific mortality was not increased in biopsied patients as compared with non-biopsied patients.<sup>36</sup>

One of the limitations of this study was the relatively short follow-up for some of the cases included in analyses, with 5 months being the shortest interval; however, it was still possible to show statistically significant differences between genotype results.

Although, MSA is a highly successful genotyping technique at our centre for UM samples yielding a small amount of DNA, next-generation sequencing (NGS) panels are increasingly being used for this type of analysis. This comprises broader pan cancer panels,<sup>37,38</sup> whole exome sequencing<sup>39</sup> and targeted NGS panels,<sup>40</sup> including a bespoke NGS UM panel quite advanced in its development at our own centre,<sup>41</sup> based on The Cancer Genome Atlas mutational data,<sup>42</sup> which also successfully obtains reliable genotyping data in previously irradiated tumours.

In summary, we have shown that MSA is a reliable genotyping technique that can provide Chr3 classification in irradiated and non-irradiated UM. In addition, melanoma-specific mortality is not increased when UM are biopsied prior to radiotherapy.

## Author affiliations

- <sup>1</sup>Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK  
<sup>2</sup>Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK  
<sup>3</sup>Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Liverpool, UK  
<sup>4</sup>Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Liverpool, UK  
<sup>5</sup>Liverpool Ocular Oncology Centre, Royal Liverpool University Hospital, Liverpool, UK  
<sup>6</sup>Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK  
<sup>7</sup>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK  
<sup>8</sup>Department of Medical Physics and Clinical Engineering, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK

**Acknowledgements** The authors would like to thank and acknowledge the Biomedical Scientists of the Ophthalmic Pathology team at the Liverpool Clinical Laboratories, Mr Simon Biddolph and Mrs Anna Ikin and Mr Gary Cheetham for maintaining of the database of the Liverpool Ocular Oncology Centre based at the Liverpool University Hospitals, UK.

**Contributors** ST, SEC, HK: Design of study; ST: Undertaking microsatellite analysis; ST, SEC, AT, AE, HK: Evaluation of laboratory data with clinical data and outcomes; All authors: Interpretation of results; All authors: Manuscript writing; All authors: Critical review of manuscript.

**Funding** This work was supported by the Eye Tumour Research Fund Charitable Funds, Royal Liverpool University Hospital, UK, grant number (A091/CF).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Ethics approval** Approval for the study was obtained from the Health Research Authority South Central - Hampshire B Research Ethics Committee (REC ref 15/SC/0611).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information. Deidentified participant data is available from the corresponding author upon reasonable request. ORCID ID. 0000-0001-7693-7279, or sophie.thornton@liv.ac.uk. Conditions of reuse dependent upon ethical approval and appropriate data transfer agreement.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

## ORCID iDs

Sophie Thornton <http://orcid.org/0000-0001-7693-7279>  
 Rumana Hussain <http://orcid.org/0000-0001-8208-5009>

## REFERENCES

- Tschentscher F, Prescher G, Zeschnigk M, et al. Identification of chromosomes 3, 6, and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. *Cancer Genet Cytogenet* 2000;122:13–17.
- Shields CL, Ganguly A, Materin MA, et al. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases. *Trans Am Ophthalmol Soc* 2007;105:1017–53.
- Abdel-Rahman MH, Christopher BN, Faramawi MF, et al. Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma. *Modern Pathology* 2011;24:954–62.
- Thomas S, Pütter C, Weber S, et al. Prognostic significance of chromosome 3 alterations determined by microsatellite analysis in uveal melanoma: a long-term follow-up study. *Br J Cancer* 2012;106:1171–6.
- Shields JA, Shields CL. Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. *Ophthalmology* 2015;122:414–28.
- Macdonald ECA, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uveal melanoma in Scotland. *Br J Ophthalmol* 2011;95:1691–5.
- Shields CL, Shields JA, Cater J, et al. Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. *Arch Ophthalmol* 2000;118:1219–28.
- Damato B, Kacperek A, Errington D, et al. Proton beam radiotherapy of uveal melanoma. *Saudi J Ophthalmol* 2013;27:151–7.
- Rivard MJ, Melhus CS, Sioshansi S, et al. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs. *Brachytherapy* 2008;7:327–35.
- Reichstein D, Karan K. Plaque brachytherapy for posterior uveal melanoma in 2018: improved techniques and expanded indications. *Curr Opin Ophthalmol* 2018;29:191–8.
- Damato B, Patel I, Campbell IR, et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. *Int J Radiat Oncol Biol Phys* 2005;63:385–91.
- Seddon JM, Gragoudas ES, Egan KM, et al. Uveal melanomas near the optic disc or fovea. visual results after proton beam irradiation. *Ophthalmology* 1987;94:354–61.
- Sikuade MJ, Salvi S, Rundle PA, et al. Outcomes of treatment with stereotactic radio-surgery or proton beam therapy for choroidal melanoma. *Eye* 2015;29:1194–8.
- Hussain RN, Kalirai H, Groenewald C, et al. Prognostic biopsy of choroidal melanoma after proton beam radiation therapy. *Ophthalmology* 2016;123:2264–5.
- Angi M, Kalirai H, Taktak A, et al. Prognostic biopsy of choroidal melanoma: an optimised surgical and laboratory approach. *Br J Ophthalmol* 2017;101:1143–6.
- Damato B. Does ocular treatment of uveal melanoma influence survival? *Br J Cancer* 2010;103:285–90.
- Foulds WS. The local excision of choroidal melanoma. *Trans Ophthalmol Soc U K* 1973;93:343–6.
- Damato B, Groenewald C, McGalliard J, et al. Endoresection of choroidal melanoma. *Br J Ophthalmol* 1998;82:213–8.
- Malbran ES, Charles D, Garrido CM, et al. Iridocyclectomy technique and results. *Ophthalmology* 1979;86:1048–66.
- Lake SL, Coupland SE, Taktak AFG, et al. Whole-Genome microarray detects deletions and loss of heterozygosity of chromosome 3 occurring exclusively in metastasizing uveal melanoma. *Invest Ophthalmol Vis Sci* 2010;51:4884–91.
- FEH J. *Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis*. New York: Springer, 2001.
- Gray RJ. A Class of  $\chi^2$ -Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. *The Annals of Statistics* 1988;16:1141–54.
- Shields CL, Ganguly A, Bianciotto CG, et al. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. *Ophthalmology* 2011;118:396–401.
- Damato B, Coupland SE. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. *Eye* 2009;23:2152–62. quiz 612.
- Mensink HW, Vaarwater J, Kilic E, et al. Chromosome 3 Intratumor heterogeneity in uveal melanoma. *Invest. Ophthalmol. Vis. Sci.* 2009;50:500–4.
- Dopierala J, Damato BE, Lake SL, et al. Genetic heterogeneity in uveal melanoma assessed by multiplex ligation-dependent probe amplification. *Invest Ophthalmol Vis Sci* 2010;51:4898–905.
- Coupland SE, Kalirai H, Ho V, et al. Concordant chromosome 3 results in paired choroidal melanoma biopsies and subsequent tumour resection specimens. *Br J Ophthalmol* 2015;99:1444–50.
- Wackernagel W, Tarmann L, Mayer C, et al. Genetic analysis of uveal melanoma by array comparative genomic hybridization before and after radiotherapy. *Spektrum der Augenheilkunde* 2013;27:286–91.
- Dogrusöz M, Kroes WGM, van Duinen SG, et al. Radiation treatment affects chromosome testing in uveal melanoma. *Invest Ophthalmol Vis Sci* 2015;56:5956–64.
- Matet A, Ait Raïs K, Malaise D, et al. Comparative cytogenetic abnormalities in paired choroidal melanoma samples obtained before and after proton beam irradiation by transscleral fine-needle aspiration biopsy and endoresection. *Cancers* 2019;11:1173.
- Glasgow BJ, Brown HH, Maria Zargoza A, et al. Quantitation of tumor seeding from fine needle aspiration of ocular melanomas. *Am J Ophthalmol* 1988;105:538–46.
- Mashayekhi A, Lim RP, Shields CL, et al. Extraocular extension of CILIOCHOROIDAL melanoma after transscleral fine-needle aspiration biopsy. *Retin Cases Brief Rep* 2016;10:289–92.
- Raja V, Russo A, Coupland S, et al. Extraocular seeding of choroidal melanoma after a transretinal biopsy with a 25-gauge vitrector. *Retin Cases Brief Rep* 2011;5:194–6.
- Scheffler AC, Gologorsky D, Marr BP, et al. Extraocular extension of uveal melanoma after fine-needle aspiration, vitrectomy, and open biopsy. *JAMA Ophthalmol* 2013;131:1220–4.
- Caminal JM, Sanz S, Carreras M. Epibulbar seeding at the site of a transvitreal fine-needle aspiration biopsy. *Arch Ophthalmol* 2006;124:587–9.
- Bagger M, Smidt-Nielsen I, Andersen MK, et al. Long-Term metastatic risk after biopsy of posterior uveal melanoma. *Ophthalmology* 2018;125:1969–76.
- Afshar AR, Damato BE, Stewart JM, et al. Next-Generation sequencing of uveal melanoma for detection of genetic alterations predicting metastasis. *Transl Vis Sci Technol* 2019;8:18.
- Shain AH, Bagger MM, Yu R, et al. The genetic evolution of metastatic uveal melanoma. *Nat Genet* 2019;51:1123–30.
- Rodrigues M, Mobuchon L, Houy A, et al. Evolutionary Routes in Metastatic Uveal Melanomas Depend on MBD4 Alterations. *Clinical Cancer Research* 2019;25:5513–24.
- Smit KN, van Poppel NM, Vaarwater J, et al. Combined mutation and copy-number variation detection by targeted next-generation sequencing in uveal melanoma. *Modern Pathology* 2018;31:763–71.
- Thornton S, Kalirai H, Sibbring J, et al. Developing next generation sequencing (NGS) panels for uveal melanoma to detect copy number and single nucleotide variants. *J Pathol* 2019;248:S13.
- Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. *Cancer Cell* 2017;32:204–20.

Supplementary Table 2.

Marker		Marker position in Chr 3	Amplicon size	Repeat	Primer label/colour
Name	Primer sequence	Arm			
<b>D3S3050</b>	For_TGGTGGTATGCATTTGTCAG Rev_ATTCCCTGACTTCAAGTGCA	p (26-24.2)	230-250bp	Tetranucleotide	HEX/green
<b>D3S1263</b>	For_CTAAGTAGGCAGTTGGTATTATTT C Rev_ATCACAGCAGGGGTTTCATTTTT C	p (25.3)	200-230bp	Dinucleotide	FAM/blue
<b>D3S1300</b>	For_GAATAAACCTGAGAATCATCCCT Rev_CATGACGTTCCCTTGTAGTGTTT	p (14.2)	110-158bp	Dinucleotide	FAM/blue
<b>D3S2406</b>	For_GGCTGGATGATCCACTTTAA Rev_CCAGTTCCTGCTTCTTGAAA	p (13)	306-350bp	Tetranucleotide	TET/blue
<b>D3S3045</b>	For_ACCAAATGAGACAGTGGCAT Rev_ATGAGGACGGTTGACATCTG	q (13.12)	180-200bp	Tetranucleotide	FAM/blue
<b>D3S1744</b>	For_TTTAAGCGGAAGGAAGTGTG Rev_CTGGCCCCATCTCTCTAT	q (24-25)	131-167bp	Tetranucleotide	TET/blue
<b>D3S2421</b>	For_AGCCATGATCACACCACTCT Rev_GGTCTTCATCATGCATCCTC	q (26.31)	297-310bp	Tetranucleotide	FAM/blue
<b>D3S1311</b>	For_GGAAGTTTCAGCCAACG Rev_TTAGTCCCACTGATGTTACATTT	q (29)	134-152bp	Dinucleotide	HEX/green



Supplementary Table 1. Genotype specific demographics of 407 UM genotyped by microsatellite analysis

	All Tumors (n=407)	M3 (n=97)	D3 (n=256)	Partial loss of 3q (n=16)	AI (n=26)	Unclassifiable (n=12)
<b>Median age at PM (years)</b>	61 (12 – 93)	65 (14 – 93)	59 (16 – 92)	60 (12 – 81)	62 (16 – 82)	57.5 (35 – 79)
<b>Female</b>	211	52	128	9	16	5
<b>Male</b>	196	45	128	7	9	7
<b>Median LBD (mm)</b>	11.2 (1.82 – 20.8)	13.4 (4.4 – 20.8)	10.5 (1.82 – 19.5)	10.5 (5.4 – 16.1)	10.5 (5.8 – 18.7)	10.7 (7.7 – 16.2)
<b>Median UH (mm)</b>	3.1 (0.9 – 18.5)	4.2 (0.9 – 18.5)	2.7 (0.9 – 12.6)	3.2 (1.1 – 10.1)	3.0 (0.9 – 9.8)	2.9 (1.0 – 6.2)
<b>AJCC Stage</b>						
1	186	20	136	8	14	8
2	146	47	82	5	9	3
3	59	21	32	3	2	1
4	16	9	6	-	1	-
<b>Cell Type</b>						
Epithelioid	116	61	44	2	5	4
Spindle	261	34	192	12	15	8
Indeterminate	30	2	20	2	6	-
<b>Ciliary Body Involvement</b>						
Yes	53	20	24	4	3	-
No	354	77	222	12	23	12
<b>Extraocular Extension</b>						
Yes	5	3	2	-	-	-
No	402	94	254	16	25	12
<b>Biopsy taken Pre/Post RXT</b>						
Pre	172	48	100	8	9	6
Post	180	33	118	6	15	6
<b>Follow-Up</b>						
Months	54 (5 – 368)	50 (6 – 95)	51.7 (5 – 170)	21.2 (6 – 90)	52.6 (9 – 92)	49.4 (4 – 82)
<b>Status</b>						
Alive	348	62	242	14	24	10
Metastatic death	35	27	5	2	-	1
Death other causes	20	7	9	-	2	1